PHARMARESOURCES (SHANGHAI) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.95 CNY | -2.23% |
|
-1.80% | +0.42% |
| Apr. 24 | PharmaResources Co., Ltd. Proposes Final Cash Dividend for the Year 2023 | CI |
| Apr. 23 | PharmaResources Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The firm trades with high earnings multiples: 26.63 times its 2024 earnings per share.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +0.42% | 536M | - | ||
| -0.09% | 42.12B | B | ||
| +49.62% | 42.05B | A | ||
| -4.96% | 29.18B | C | ||
| +11.18% | 26.02B | B- | ||
| -21.95% | 18.9B | B | ||
| +8.61% | 13.21B | B+ | ||
| +24.73% | 12.17B | B+ | ||
| +28.31% | 12.16B | C+ | ||
| -6.26% | 11.42B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 301230 Stock
- Ratings PharmaResources (Shanghai) Co., Ltd.
